Four years ago, Boehringer Ingelheim agreed to pay roughly $650 million to settle claims that its blood thinner Pradaxa caused excessive bleeding. But when the pharmaceutical giant was hit with a new wave of Pradaxa suits, Boehringer changed course. This time, it decided to go to court and fight.

The company turned to Covington & Burling’s Phyllis Jones, who has racked up a series of wins on behalf of drug companies facing product liability suits, including Eli Lilly and Co.